Nanostart AG: Mr Neef's appointment as CEO extended

  • Neef's activity as CEO has been extended

Frankfurt am Main – 20 March 2015 – Nanostart AG announces that according to the Supervisory Board's resolution, dated 19 March 2015, Mr Neef's appointment as CEO was extended until 31 December 2015. Up to now, Mr Neef was appointed as interim CEO.

Read more ...

Nanostart AG: New Board of Directors appointed

  • Bernd Förtsch has become member of the Board of Directors

Frankfurt am Main – 10 February 2015 – The Nanostart AG announces that the District Court Frankfurt am Main has met the request of the Executive Board of the Nanostart AG by means of the decision in January 2015, appointing Mr Bernd Förtsch as member of the company’s Board of Directors.


Read more ...

Nanostart AG publishes annual accounts for the 2013 financial year

  • Nanostart AG achieved a net profit of EUR 0.34 million after tax
  • Company virtually free of liabilities (previous year EUR 3.81 million)
  • Operating expenses reduced by 54.8 percent

Frankfurt / Main – July 1, 2014 - The Frankfurt-based nanotechnology investment company Nanostart AG is today publishing its annual financial statements for the 2013 financial year. The company posted a net profit of EUR 0.34 million according to HGB (German Commercial Code).

Read more ...

Nanostart-holding MagForce AG: MagForce AG and MagForce USA, Inc. Announce FDA Pre-IDE Meeting


Frankfurt / Berlin, Germany and Nevada, USA - May 5, 2014 – Nanostart-holding MagForce, a leading medical device company in the field of nanomedicine focused on oncology, together with its subsidiary MagForce USA, Inc. are pleased to report that an in-person meeting was held with the U.S. Food and Drug Administration’s (FDA) Center for Devices and Radiological Health to discuss FDA’s response to MagForce’s NanoTherm® Therapy Pre-Submission of late December, 2013.

Read more ...

MagForce Shareholder letter 2015


Frankfurt am Main / Berlin and Nevada, USA - February 5, 2015 – Nanostart-holding MagForce, a medical technology company that focuses on the field of oncology and is a leader in the nanotechnology sector, today published the letter to shareholders.

Read more ...

Press Contact

Tel.:  +49 (0)69-2193 96 00
Fax.:  +49 (0)69-2193 96 150